<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35243932</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1365-2060</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>54</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of medicine</Title>
          <ISOAbbreviation>Ann Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Neurotrophic keratopathy: current challenges and future prospects.</ArticleTitle>
        <Pagination>
          <StartPage>666</StartPage>
          <EndPage>673</EndPage>
          <MedlinePgn>666-673</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/07853890.2022.2045035</ELocationID>
        <Abstract>
          <AbstractText>Neurotrophic keratopathy (NK), or neurotrophic keratitis, is a degenerative condition that results from decreased innervation to the cornea. The cornea is innervated by the ophthalmic branch of the trigeminal nerve. Neurotrophic keratopathy is most commonly caused by herpes keratitis however, any condition that disrupts the normal corneal innervation can cause NK. Neurotrophic keratopathy is a clinical diagnosis and is classified into three stages based on the disease severity. Stage 1 has mild epithelial defects, such as punctate keratopathy, stage 2 disease has persistent epithelial defects, and stage 3 is defined by the presence of ulcers. Current treatment modalities consist of medical and surgical options. Stage 1 is treated with lubrication through artificial tears, eyelid taping, and punctal plug/cautery. Stage 2 treatment can involve therapeutic contact lenses, topical autologous or allogenic serum, tarsorrhaphy, botulinum toxin injections, and possibly anti-inflammatory medications. Stage 3 disease may require human nerve growth factor, amniotic membrane transplantation, conjunctival flap, or corneal neurotization. New therapies, such as matrix regenerating therapy, plasma rich in growth factors, Thymosin β4, Substance P/Insulin like growth factor-1, and nicergoline represent exciting future options.KEY MESSAGESNeurotrophic keratopathy is a rare degenerative disease defined by decreased innervation to the cornea that is associated with significant morbidity.Treatment options range from lubrication alone to various medical and surgical treatments.Matrix regenerating therapy, plasma rich in growth factors, Thymosin β4, Substance P/Insulin like growth factor-1, and nicergoline are exciting novel therapies that will influence how neurotrophic keratopathy is treated in the future.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>NaPier</LastName>
            <ForeName>Erin</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Camacho</LastName>
            <ForeName>Matthew</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McDevitt</LastName>
            <ForeName>Timothy F</ForeName>
            <Initials>TF</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Ophthalmology, Department of Surgery, John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sweeney</LastName>
            <ForeName>Adam R</ForeName>
            <Initials>AR</Initials>
            <Identifier Source="ORCID">0000-0001-6419-4412</Identifier>
            <AffiliationInfo>
              <Affiliation>Section of Ophthalmology, Department of Surgery, John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ann Med</MedlineTA>
        <NlmUniqueID>8906388</NlmUniqueID>
        <ISSNLinking>0785-3890</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003315" MajorTopicYN="N">Cornea</DescriptorName>
          <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003317" MajorTopicYN="Y">Corneal Dystrophies, Hereditary</DescriptorName>
          <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007634" MajorTopicYN="Y">Keratitis</DescriptorName>
          <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016067" MajorTopicYN="Y">Nerve Transfer</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020433" MajorTopicYN="Y">Trigeminal Nerve Diseases</DescriptorName>
          <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Mackie classification</Keyword>
        <Keyword MajorTopicYN="Y">Neurotrophic keratitis</Keyword>
        <Keyword MajorTopicYN="Y">autologous serum drops</Keyword>
        <Keyword MajorTopicYN="Y">corneal anaesthesia</Keyword>
        <Keyword MajorTopicYN="Y">corneal nerves</Keyword>
        <Keyword MajorTopicYN="Y">corneal ulcer</Keyword>
        <Keyword MajorTopicYN="Y">neurotization</Keyword>
        <Keyword MajorTopicYN="Y">neurotrophic keratopathy</Keyword>
        <Keyword MajorTopicYN="Y">novel therapies</Keyword>
      </KeywordList>
      <CoiStatement>No conflicting relationship exists for any author.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>8</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35243932</ArticleId>
        <ArticleId IdType="pmc">PMC8903790</ArticleId>
        <ArticleId IdType="doi">10.1080/07853890.2022.2045035</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bonini S, Rama P, Olzi D, et al. . 
Neurotrophic keratitis. Eye. 2003;17(8):989–995.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14631406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sacchetti M, Lambiase A.. 
Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol. 2014;8:571–579.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3964170</ArticleId>
            <ArticleId IdType="pubmed">24672223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DelMonte DW, Kim T.. 
Anatomy and physiology of the cornea. J Cataract Refract Surg. 2011;37(3):588–598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21333881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Müller LJ, Marfurt CF, Kruse F, et al. . 
Corneal nerves: structure, contents and function. Exp Eye Res. 2003;76(5):521–542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12697417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sigelman S, Friedenwald JS.. 
Mitotic and wound-healing activities of the corneal epithelium; effect of sensory denervation. AMA Arch Ophthalmol. 1954;52(1):46–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13170864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Versura P, Giannaccare G, Pellegrini M, et al. . 
Neurotrophic keratitis: current challenges and future prospects. Eye Brain. 2018;10:37–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6029608</ArticleId>
            <ArticleId IdType="pubmed">29988739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saad S, Abdelmassih Y, Saad R, et al. . 
Neurotrophic keratitis: frequency, etiologies, clinical management and outcomes. Ocul Surf. 2020;18(2):231–236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31759182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonini S, Lambiase A, Rama P, et al. . 
Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology. 2000;107(7):1347–1351. discussion 1351–1352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10889110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ammar DA, Noecker RJ, Kahook MY.. 
Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010;27(11):837–845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20931366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kahook MY, Ammar DA.. 
In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells. J Ocul Pharmacol Ther. 2010;26(3):259–263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20565312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semeraro F, Forbice E, Romano V, et al. . 
Neurotrophic keratitis. Ophthalmologica. 2014;231(4):191–197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24107451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dworkin RH, Johnson RW, Breuer J, et al. . 
Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(Suppl 1):S1–S26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17143845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhatti MT, Patel R.. 
Neuro-ophthalmic considerations in trigeminal neuralgia and its surgical treatment. Curr Opin Ophthalmol. 2005;16(6):334–340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16264342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mertsch S, Alder J, Dua HS, et al. . 
[Pathogenesis and epidemiology of neurotrophic keratopathy]. Ophthalmologe. 2019;116(2):109–119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30478498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murray LT, McCormack J, Grobeiu I, et al. . 
Development of the neurotrophic keratopathy questionnaire: qualitative research. J Patient Rep Outcomes. 2020;4(1):30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7198680</ArticleId>
            <ArticleId IdType="pubmed">32367451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mackie IN, Keratitis I, Fraunfelder F, et al., editors. Current ocular therapy. Philadelphia, PA: WB Saunders; 1995. p. 452–454.</Citation>
        </Reference>
        <Reference>
          <Citation>Matsumoto Y, Dogru M, Goto E, et al. . 
Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004;111(6):1115–1120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15177961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heigle TJ, Pflugfelder SC.. 
Aqueous tear production in patients with neurotrophic keratitis. Cornea. 1996;15(2):135–138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8925660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witsberger E, Schornack M.. 
Scleral lens use in neurotrophic keratopathy: a review of current concepts and practice. Eye Contact Lens. 2021;47(3):144–148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33009259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishida T, Chikama TI, Morishige N, et al. . 
Persistent epithelial defects due to neurotrophic keratopathy treated with a substance p-derived peptide and insulin-like growth factor 1. Jpn J Ophthalmol. 2007;51(6):442–447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18158595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan Q, Angelina A, Marrone M, et al. . 
Autologous serum eye drops for dry eye. Cochrane Database Syst Rev. 2017;2(2):CD009327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5510593</ArticleId>
            <ArticleId IdType="pubmed">28245347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeng BH, Dupps WJ.. 
Autologous serum 50% eyedrops in the treatment of persistent corneal epithelial defects. Cornea. 2009;28(10):1104–1108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19730088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Versura P, Buzzi M, Giannaccare G, et al. . 
Targeting growth factor supply in keratopathy treatment: comparison between maternal peripheral blood and cord blood as sources for the preparation of topical eye drops. Blood Transfus Trasfus Sangue. 2016;14(2):145–151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4781782</ArticleId>
            <ArticleId IdType="pubmed">26192781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernabei F, Roda M, Buzzi M, et al. . 
Blood-Based treatments for severe dry eye disease: the need of a consensus. JCM. 2019;8(9):1478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6780616</ArticleId>
            <ArticleId IdType="pubmed">31533289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon KC, You IC, Im SK, et al. . 
Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis. Ophthalmology. 2007;114(9):1637–1642.e2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17382396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Erdem E, Yagmur M, Harbiyeli I, et al. . 
Umbilical cord blood serum therapy for the management of persistent corneal epithelial defects. Int J Ophthalmol. 2014;7(5):807–810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4206885</ArticleId>
            <ArticleId IdType="pubmed">25349797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trinh T, Mimouni M, Santaella G, et al. . 
Surgical management of the ocular surface in neurotrophic keratopathy: amniotic membrane, conjunctival grafts, lid surgery, and neurotization. Eye Contact Lens. 2021;47(3):149–153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33196502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adams GGW, Kirkness CM, Lee JP.. 
Botulinum toxin a induced protective ptosis. Eye. 1987;1(5):603–608.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3446541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petroutsos G, Guimaraes R, Giraud JP, et al. . 
Corticosteroids and corneal epithelial wound healing. Br J Ophthalmol. 1982;66(11):705–708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1039904</ArticleId>
            <ArticleId IdType="pubmed">6896993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lambiase A, Rama P, Aloe L, et al. . 
Management of neurotrophic keratopathy. Curr Opin Ophthalmol. 1999;10(4):270–276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10621535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lambiase A, Sacchetti M, Bonini S.. 
Nerve growth factor therapy for corneal disease. Curr Opin Ophthalmol. 2012;23(4):296–302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22543481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pflugfelder SC, Massaro-Giordano M, Perez VL, et al. . 
Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: a multicenter randomized Vehicle-Controlled pivotal trial. Ophthalmology. 2020;127(1):14–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31585826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deeks ED, Lamb YN.. 
Cenegermin: a review in neurotrophic keratitis. Drugs. 2020;80(5):489–494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32185680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khokhar S, Natung T, Sony P, et al. . 
Amniotic membrane transplantation in refractory neurotrophic corneal ulcers: a randomized, controlled clinical trial. Cornea. 2005;24(6):654–660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16015082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turkoglu E, Celik E, Alagoz G.. 
A comparison of the efficacy of autologous serum eye drops with amniotic membrane transplantation in neurotrophic keratitis. Semin Ophthalmol. 2014;29(3):119–126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23758337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gundersen T, Pearlson HR.. 
Conjunctival flaps for corneal disease: their usefulness and complications. Trans Am Ophthalmol Soc. 1969;67:78–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1310332</ArticleId>
            <ArticleId IdType="pubmed">5381310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terzis JK, Dryer MM, Bodner BI.. 
Corneal neurotization: a novel solution to neurotrophic keratopathy. Plast Reconstr Surg. 2009;123(1):112–120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19116544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koaik M, Baig K.. 
Corneal neurotization. Curr Opin Ophthalmol. 2019;30(4):292–298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31033738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sweeney AR, Wang M, Weller CL, et al. . 
Outcomes of corneal neurotisation using processed nerve allografts: a multicentre case series. Br J Ophthalmol. 2022;106(3):326–330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33199302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leyngold I, Weller C, Leyngold M, et al. . 
Endoscopic corneal neurotization: technique and initial experience. Ophthalmic Plast Reconstr Surg. 2018;34(1):82–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29194285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ong ES, Jeng BH.. 
Current and future therapies for persistent corneal epithelial defects and neurotrophic keratopathy. Curr Opin Ophthalmol. 2021;32(3):262–267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33630785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Zazzo A, Coassin M, Varacalli G, et al. . 
Neurotrophic keratopathy: pros and cons of current treatments. Ocul Surf. 2019;17(4):619–623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31526824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cochener B, Zagnoli C, Hugny-Larroque C, et al. . 
Healing of resistant corneal neurotrophic ulcers using a matrix regenerating agent. J Fr Ophtalmol. 2019;42(2):159–165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30573293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aifa A, Gueudry J, Portmann A, et al. . 
Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers. Invest Ophthalmol Vis Sci. 2012;53(13):8181–8185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23150626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guerra M, Marques S, Gil JQ, et al. . 
Neurotrophic keratopathy: therapeutic approach using a novel matrix regenerating agent. J Ocul Pharmacol Ther. 2017;33(9):662–669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28910175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arvola RPJ, Robciuc A, Holopainen JM.. 
Matrix regeneration therapy: a case series of corneal neurotrophic ulcers. Cornea. 2016;35(4):451–455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26845313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>López-Plandolit S, Morales MC, Freire V, et al. . 
Plasma rich in growth factors as a therapeutic agent for persistent corneal epithelial defects. Cornea. 2010;29(8):843–848.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20508516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabater AL, Mousa HM, Quinones X, et al. . 
Use of autologous plasma rich in growth factors fibrin membrane in the surgical management of ocular surface diseases. Int Ophthalmol. 2021;41(7):2347–2358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33745034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao K, Leveque C, Pflugfelder SC.. 
Corneal nerve regeneration in neurotrophic keratopathy following autologous plasma therapy. Br J Ophthalmol. 2010;94(5):584–591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3575078</ArticleId>
            <ArticleId IdType="pubmed">19965821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunn SP, Heidemann DG, Chow CYC, et al. . 
Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta 4. Arch Ophthalmol. 2010;128(5):636–638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20457990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SY, Choi JS, Joo CK.. 
Effects of nicergoline on corneal epithelial wound healing in rat eyes. Invest Ophthalmol Vis Sci. 2009;50(2):621–625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18836171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee YC, Kim SY.. 
Treatment of neurotrophic keratopathy with nicergoline. Cornea. 2015;34(3):303–307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25625360</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
